Michael Price, Executive Vice President & Chief Financial Officer
Michael Price has served as Novelion's executive vice president and chief financial officer since July 2018 and was senior vice president and chief financial officer since December 2017. Prior to Novelion, Michael Price was most recently vice president and chief financial officer for Noven Pharmaceuticals, Inc., a NASDAQ-listed company until its acquisition by Hisamitsu Pharmaceutical Company. In his role at Noven, Mr. Price was directly involved with the development and execution of strategy that scaled the Company's commercial organization and significantly increased revenues. Prior to Noven, Mr. Price was vice president, chief financial officer, treasurer, secretary and a member of the board of directors for Bentley Pharmaceuticals, a New York Stock Exchange-listed company until Teva Pharmaceutical Industries' 2008 acquisition. Mr. Price is a certified public accountant. He holds a bachelor of science degree in business administration (accounting) from Auburn University and a master of business administration degree from Florida State University.
Ben Harshbarger, Interim Chief Executive Officer & General Counsel
Ben Harshbarger has served as Novelion's interim chief executive officer since November 2018, general counsel since November 2016, and was general counsel for Aegerion Pharmaceuticals since September 2016. Prior to that, he served as Aegerion's acting general counsel, VP, EMEA legal counsel and as vice president, deputy general counsel. Before joining Aegerion, Mr. Harshbarger served as senior director, corporate counsel at Cubist Pharmaceuticals, Inc. from March 2008 to March 2012, and senior director, deputy general counsel at ViaCell, Inc. from March 2006 to March 2008. Mr. Harshbarger served in several legal positions of increasing responsibility at Biogen Idec from November 2001 to March 2006 and served as an associate at the law firm of Mintz Levin from 1996 to 2001. Mr. Harshbarger holds a J.D. from Boston College Law School and a B.A. from the University of Richmond.
Roger Louis, Global Chief Compliance Officer, Head of Research & Development
Roger Louis has served as head of research and development since October 2018, global chief compliance officer since November 2016, and was previously Aegerion Pharmceuticals' senior vice president, global chief compliance officer since November 2015. Mr. Louis has extensive experience in compliance and risk management, having served most recently as senior vice president, compliance & risk management, chief compliance officer at Cubist Pharmaceuticals prior to its acquisition by Merck. Mr. Louis joined Cubist from Biogen Idec where he was senior vice president, chief compliance officer. From 1997 to 2012, he held positions of increasing responsibility at Genzyme Corporation, including senior vice president, chief compliance officer. Mr. Louis began his legal career as an associate at Hale & Dorr in Boston where he practiced corporate and securities law. Mr. Louis received his J.D. from University of Chicago School of Law and his B.A. from Tufts University.
Linda Buono, Senior Vice President, Human Resources
Linda Buono has served as Novelion's senior vice president, human resources, since November 2016. Prior to Novelion, Ms. Buono was Aegerion's senior vice president of human resources. Prior to Aegerion, Ms. Buono spent more than 25 years at Immunogen where she held a variety of leadership positions in Human Resources. She is effective in managing all the critical tasks and responsibilities of the company’s HR function and has facilitated recruitment of top talent across the organization. Importantly, she possesses the critical soft skills needed to significantly improve the success of the company. Her core attributes include courage, judgment, influence, political agility and effective communication, all of which are having an impact on the improved culture of the organization.
Suzanne Bruhn, Ph.D.
Suzanne Bruhn is currently president and chief executive officer and a member of the Board of Directors of Tiaki Therapeutics. Dr. Bruhn previously served as the president and chief executive officer of Proclara Biosciences, Inc. from April 2017 to September 2018. Prior to joining Proclara, Dr. Bruhn served as president and chief executive officer of Promedior, Inc. She also served as a member of the board of directors of Raptor Pharmaceuticals from 2011 until it was acquired by Horizon Pharma in 2016. Previously, Dr. Bruhn served in a number of roles of increasing responsibility at Shire from 1998 until 2012, culminating as senior vice president, strategic planning and program management. Dr. Bruhn currently also serves on the board of directors of Aeglea BioTherapeutics, Inc., a publicly traded biotechnology company focused on the treatment of rare genetic diseases and cancer, and Pliant Therapeutics, a private biotechnology company. Dr. Bruhn received her B.S. degree in Chemistry from Iowa State University and her Ph.D. in Chemistry from Massachusetts Institute of Technology.
Mark Corrigan, M.D., Chair
Mark Corrigan is currently Chief Executive Officer of Correvio Pharma Corporation. Dr. Corrigan was previously president and chief executive officer of Zalicus Inc, and prior to that, he was executive vice president, research & development of Sepracor Inc. (now Sunovion Pharmaceuticals). Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, Inc., most recently as group vice president of global clinical research and experimental medicine. Dr. Corrigan currently serves on the board of directors of Cardiome Pharma Corp. (NASDAQ: CRME) and on the supervisory board of Nabriva Therapeutics AG (NASDAQ: NBRV). He previously served as a director of CoLucid Pharmaceuticals, Inc., Avanir Pharmaceuticals, Inc., EPIRUS Biopharmaceuticals, Inc. and Cubist Pharmaceuticals, Inc. He was chairman of the board of EPIRUS and served on the audit committee and nominating and governance committee and chaired the scientific affairs committee of Cubist’s board. Dr. Corrigan spent five years in academic research at the University of North Carolina Medical School, focusing on psychoneuroendocrinology. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.
John Orloff, M.D.
John Orloff, M.D., is executive vice president, head of research & development of Alexion. Dr. Orloff has 20 years of experience in the biopharmaceutical industry and deep expertise spanning various stages of clinical and non-clinical development, including developing medicines for rare diseases. Prior to joining Alexion, Dr. Orloff served as executive vice president, head of research & development at Novelion. He previously served with Baxalta as global head of R&D and chief scientific officer, where he advanced the company's pipeline and oversaw regulatory approval of 10 unique products and two devices. He also held executive R&D roles with Baxter International, Merck Serono, Novartis and Merck Research Laboratories. Prior to joining the biopharmaceutical industry in 1997, Dr. Orloff was with the Yale School of Medicine for seven years. Dr. Orloff received a Bachelor of Arts from Dartmouth College, and a M.D. from the University of Vermont College of Medicine. He completed his medical training at the University of Pittsburgh Medical Center and Yale University School of Medicine.
Stephen L. Sabba, M.D.
Prior to being appointed to Novelion's Board of Directors, Stephen L. Sabba, M.D. was a director of QLT since 2012, chairman of the audit and risk committee and a member of the scientific review and compensation committees. Currently, Dr. Sabba is also a partner and health care portfolio manager at Knott Partners, LP (since 2006), an investment fund, and a director of Ligand (since 2008), a public biotechnology company. Previously, he was a partner and director of research with Kilkenny Capital Management (2001 to 2006), a Chicago-based hedge fund. Dr. Sabba received his medical degree from the New York University School of Medicine, and completed a residency in internal medicine and a fellowship in gastroenterology at the Veterans Administration Medical Center in New York City. He earned a Bachelor of Science degree with honors at Cornell University.
Donald K. Stern
Prior to being appointed to Novelion's Board of Directors, Donald Stern was a member of Aegerion Pharmaceuticals' Board of Directors since September 2015. Mr. Stern is managing director of corporate monitoring & consulting services at Affiliated Monitors Inc., a consulting firm providing independent integrity monitoring services and compliance services across a wide range of regulated industries and professions. He is also Of Counsel to Yurko, Salvesen, & Remz, PC, a boutique litigation law firm in Boston. Mr. Stern was United States Attorney for the District of Massachusetts from 1993 to 2001. He was also the chair of the U.S. Attorney General's Advisory Committee from 1996 to 1998. Mr. Stern served as the chief legal counsel to Governor Michael S. Dukakis from 1987 to 1990. He also spent seven years (1975-1982) as an assistant attorney general in the Massachusetts Attorney General's office, where he held several positions, including chief of the government bureau. Previously, Mr. Stern was a partner at three major law firms, Cooley LLP, Bingham McCutchen LLP, and Hale and Dorr LLP (now Wilmer Cutler Pickering Hale and Dorr LLP), where his law practice focused on internal investigations, white collar defense and business litigation. He has extensive experience representing companies and individuals in complex civil, criminal and regulatory matters, with clients across a spectrum of industries, including health care, pharmaceutical, and financial services. Mr. Stern was an Advisor to President Barack Obama's Justice Department Transition Team. He currently co-chairs the American Bar Association/DOJ White Collar Liaison Committee, and is a former President of the National Association of Former U.S. Attorneys. He was a liaison to the American Bar Association Task Force on Corporate Monitors. Mr. Stern has been on the faculty of Boston College Law School and Harvard Law School. He received his LL.M. from the University of Pennsylvania, his J.D. from Georgetown University Law Center, and his B.A. from Hobart College. He also received an honorary LL.D. from the New England School of Law. Mr. Stern is a member of the Board of Directors of Blue Cross and Blue Shield of Massachusetts.
John C. Thomas, Jr.
Prior to being appointed to the Novelion Board of Directors, John Thomas, Jr. was a director of QLT since 2012. Mr. Thomas has more than 38 years of experience in a variety of financial and accounting positions, with the last 28 years spent in the medical, pharmaceutical and device fields. Currently, Mr. Thomas also serves as chief financial officer, secretary and director of CorMatrix (since 2001), a privately-held medical device company, and as chief financial officer, secretary and director of Motion Reality, Inc. (since 1991), a motion capture and simulation company. Since September 2013, Mr. Thomas has served on the Board of Medovex, Inc., a publicly-traded medical device company (MDVXU). Since 2014, Mr. Thomas has served on the Board of Directors of NantKwest, Inc. a publicly-traded biotechnology company (NK). In the past ten years, Mr. Thomas served as acting chief financial officer for DemeRx, Inc. (2010 to 2011); as chief financial officer for MRI Interventions, Inc. (1998 to 2010), MiMedx Group, Inc. (2007 to 2008) and DARA BioSciences (2003 to 2009); and as a director of MRI Interventions, Inc. (2004 to 2011) and DARA BioSciences (2012). Previously, Mr. Thomas also served as a trustee and subsequently the chairman of the Finance Committee of The Walker School, a private Pre-K through 12 grade school (1999 to 2012). Mr. Thomas is a Certified Public Accountant and graduated from the University of Virginia, McIntire School of Commerce with a Bachelor of Science in Commerce degree in 1975.